News | April 29, 2023
TPAG organizes Thalassemia & SCD prevention discussion
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
The company will submit its comprehensive response on these observations to the US FDA within the stipulated time
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
Bridging the gap between histopathology and molecular pathology
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
Malaria is a life-threatening parasitic infection that is spread by the bites of mosquitoes carrying the Plasmodium parasite
Subscribe To Our Newsletter & Stay Updated
